



MOREPEN



Date: 13/05/2025

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scrip Code: 500288

Subject: Revised Press Release – “Morepen Board Proposed Dividend After 23 Years Scores Highest PAT of ₹118 Crore in FY25”

Dear Sir/ Madam,

Please find enclosed press release with the title “**Morepen Board Proposed Dividend After 23 Years Scores Highest PAT of ₹118 Crore in FY25**”.

This is for your information and dissemination on your website.

Thanking you,

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava
Company Secretary
F-12148

Encl.: a/a.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com

Morepen Board Proposed Dividend After 23 Years

Scores Highest PAT of ₹118 Crore in FY25

Gurugram, May 13, 2025 – In a landmark announcement that signals a new era of growth and financial strength, **Morepen Laboratories Ltd.** (NSE: MOREPENLAB; BSE: 500288) board has proposed to **declared a dividend (₹0.20 per share) after a gap of 23 years**, marking a defining moment in the company's four-decade legacy, subject to approval of the shareholders in the forthcoming Annual General Meeting.

The declaration comes on the back of **excellent financial results** for FY25, with **gross revenue rising to ₹1,830 crore**, up from ₹1,704 crore in FY24 — **a 7.4% year-on-year increase**. EBITDA surged **11.5% to ₹192 crore**, and **Profit After Tax jumped to ₹118 crore**, while **Earnings Per Share (EPS) climbed to ₹2.20**, up **17%** from the previous year.

Sushil Suri, Chairman & Managing Director of Morepen Laboratories Ltd., said: *"This moment is symbolic – it's not just about distributing profits; it's about rewarding trust. We always believe in the "Joy of Growing Together". Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it's time we give back."*

Morepen's **API business continued to dominate**, contributing **₹989 crore**, while the **Medical Devices segment** surged to **₹496 crore**, growing **12% year-on-year**. With **72% of API revenue coming from exports** across **80+ countries**, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.



About Morepen

Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high-quality APIs, branded generics, medical devices, and consumer wellness products to over **80 countries worldwide**. With an **installed API capacity of 514 KL**, a **14 million-strong glucometer user base**, and a rapidly expanding digital footprint, Morepen



stands at the forefront of India's health-tech evolution. Backed by **decades of trust**, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to **making quality healthcare accessible, affordable, and future-ready**.

For more details, visit www.morepen.com.

Media Contact:

Morepen Laboratories Ltd.

Corporate Office: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar – III, Sector 20, Gurugram, Haryana –122016

Email: corporate@morepen.com

Nitika Saini, Manager – Corporate Communication | +91 9818533004

Forward-Looking Statements:

This press release contains forward-looking statements based on current expectations and assumptions regarding anticipated developments and other factors affecting the company. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.